Sino Biopharmaceutical Limited
1177
Rang in Aktien
#1770
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Aktienkurs
$0.68184681
Marktkapitalisierung
$12.14B
Veränderung (1 Tag)
-1.30%
Veränderung (1 Jahr)
-28.39%
Land
HK
Handel Sino Biopharmaceutical Limited (1177)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Sino Biopharmaceutical Limited (1177)
Anzahl der ausstehenden Aktien zum June 2026: 18.05B
Laut den neuesten Finanzberichten und dem Aktienkurs von Sino Biopharmaceutical Limited beträgt die aktuelle Anzahl der ausstehenden Aktien 18.05B. Am Ende von December 2023 hatte das Unternehmen 23.39B ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Sino Biopharmaceutical Limited (1177) von 2000 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 18.05B | 4.66% |
| 2024 | 17.24B | -26.28% |
| 2023 | 23.39B | 25.61% |
| 2022 | 18.62B | -0.78% |
| 2021 | 18.77B | -0.17% |
| 2020 | 18.80B | -0.06% |
| 2019 | 18.81B | 1.42% |
| 2018 | 18.55B | 11.22% |
| 2017 | 16.68B | 0.00% |
| 2016 | 16.68B | 0.00% |
| 2015 | 16.68B | 0.00% |
| 2014 | 16.68B | 0.00% |
| 2013 | 16.68B | 0.00% |
| 2012 | 16.68B | -0.21% |
| 2011 | 16.71B | 2.01% |
| 2010 | 16.38B | 7.20% |
| 2009 | 15.28B | 0.00% |
| 2008 | 15.28B | 0.00% |
| 2007 | 15.28B | 0.00% |
| 2006 | 15.28B | 2.48% |
| 2005 | 14.91B | 10.53% |
| 2004 | 13.49B | 0.40% |
| 2003 | 13.44B | 337.20% |
| 2002 | 3.07B | 1.29% |
| 2001 | 3.03B | 17.18% |
| 2000 | 2.59B | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 445.06M | -97.53% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 105.38M | -99.42% |
US
|
